Finding a Path Forward When Migraine Medications Aren’t Possible
A candid look at the cardiovascular, pregnancy, and polypharmacy patients who don’t fit typical migraine pathways
A 32-year-old woman in her second trimester sits across from her provider describing migraines that are becoming more frequent.
A 68-year-old patient with a history of cardiovascular disease asks whether his migraine medication is still appropriate.
An older adult managing six chronic conditions wonders if adding yet another prescription is really the best option.
On paper, these patients have migraine.
In practice, they represent some of the most challenging treatment decisions we encounter. When people think about migraine treatment, they usually think about medication. And for many patients, medication is an appropriate and effective option. But what about the patients who can’t take migraine medications—or can’t take them safely?
As nurses and healthcare providers, we encounter these situations more often than many people realize. The challenge isn’t simply finding the “best” migraine treatment. It’s finding a treatment that fits the realities of the patient’s broader medical picture.
For some patients, that means navigating cardiovascular risk factors. For others, pregnancy. For many older adults, it’s the complexity of managing multiple medications at once.
These are the patients who often fall into the clinical gaps between migraine guidelines and practice.
Addressing the Remaining Gaps in Care
Migraine treatment algorithms are typically built around medications. Yet many patients don’t fit neatly into those pathways.
Consider the patient with cardiovascular disease.
Certain acute migraine therapies have historically raised concerns because of their vasoconstrictive effects or cardiovascular contraindications. Even when alternative medications are available, providers may be hesitant to add therapies in medically complex patients whose cardiovascular status requires careful management.
Pregnancy presents a different challenge.
Migraine frequently affects women during their reproductive years, and treatment decisions during pregnancy often require balancing maternal symptom control with fetal safety considerations. As a result, medication choices may become significantly more limited than they are outside of pregnancy.
Then there are patients managing multiple chronic conditions.
Polypharmacy is increasingly common, particularly among older adults. Every additional medication introduces the potential for adverse effects, drug interactions, reduced adherence, and increased treatment burden. For these patients, adding another prescription may not always be the preferred solution—even when it is technically available.
In each of these scenarios, the clinical challenge is the same:
How do we help patients when conventional medication pathways become more complicated?
Why Devices- Based Approaches May Offer Unique Advantages
Non-invasive neuromodulation devices are gaining attention because they approach migraine management from a fundamentally different direction.
Rather than introducing another medication into the body, these technologies use electrical or magnetic stimulation to influence neural pathways involved in migraine.
That distinction can be particularly relevant for patients whose treatment options are limited by safety considerations, medication intolerance, or concerns about cumulative medication burden.
Importantly, this does not mean devices are inherently “better” than medications. For many patients, medications remain highly effective and entirely appropriate.
However, there are situations where non-pharmacologic approaches offer practical advantages. Patients do not need to worry about drug-drug interactions. Systemic side effects may be reduced. And treatment can sometimes be integrated alongside existing therapies without increasing medication complexity.
For providers caring for medically complex patients, those distinctions can make neuromodulation worth discussing earlier in the treatment journey.
Setting Realistic Expectations
As enthusiasm for migraine devices grows, it’s important to avoid creating unrealistic expectations.
Neuromodulation is not a cure.
It does not work for every patient.
And it should not be presented as a replacement for evidence-based medical care.
Instead, these technologies should be viewed as one component of a broader treatment strategy that may include medications, lifestyle interventions, behavioral therapies, and ongoing clinical monitoring.
The goal is not to position devices against medications.
The goal is to expand the number of tools available to patients.
Ethical Conversations Around Treatment Access and Cost
One of the most challenging conversations providers face involves treatments that may not be fully covered by insurance.
Patients deserve transparency.
When discussing out-of-pocket therapies, the conversation should begin with clinical appropriateness—not cost.
The first question should always be:
“Could this treatment reasonably help this patient?”
Only after that determination should cost, coverage, and affordability enter the discussion.
Patients should understand the strength of the available evidence, the expected benefits, the limitations, and the financial implications before making a decision.
Equally important, they should never feel pressured toward a treatment because insurance coverage is limited elsewhere.
Ethical patient counseling requires presenting all reasonable options, discussing uncertainties openly, and supporting informed decision-making.
When handled appropriately, conversations about self-pay therapies are shared decision-making discussions.
Broadening the Clinical Approach
Some migraine patients fit neatly into established treatment algorithms.
Many do not.
The pregnant patient trying to balance symptom relief with safety considerations. The patient with cardiovascular concerns.
The older adult already managing a complex medication regimen.
These individuals remind us that effective migraine care is rarely one-size-fits-all.
As clinicians, our responsibility is not simply to prescribe treatments. It is to help patients navigate the full range of evidence-based options available to them.
Sometimes that means finding the right medication.
Sometimes it means finding an alternative pathway altogether.
And for patients who cannot easily follow traditional migraine treatment routes, those alternative pathways may be exactly what keeps the conversation moving forward.
References
- American Headache Society. Consensus Statement: Update on Integrating New Migraine Treatments Into Clinical Practice. Headache. 2021.
- American College of Obstetricians and Gynecologists. Clinical Practice Guideline: Headaches in Pregnancy and Postpartum. 2022.
- American Academy of Neurology. Practice Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults.
- Puledda F, Goadsby PJ. An update on non-invasive neuromodulation for migraine and cluster headache. Cephalalgia. 2017;37(7):685-691.
- Moisset X, Pereira B, Ciampi de Andrade D, et al. Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. The Journal of Headache and Pain. 2020;21(1):142.
- International Headache Society. Global Practice Recommendations for Migraine Management and Patient-Centered Care.
- American Geriatrics Society. Guidance on Polypharmacy and Medication Burden in Older Adults.
